Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Vaziri, J. Evans, M. Larson, P. Wilson (1993)
The impact of female hormone usage on the lipid profile. The Framingham Offspring Study.Archives of internal medicine, 153 19
V. Miller, J. Larosa, V. Barnabei, C. Kessler, G. Levin, Ann Smith-Roth, Margaret Griffin, D. Stoy, T. Bush, H. Zacur, D. Foster, Jean Anderson, A. McKenzie, S. Miller, P. Wood, M. Stefanick, R. Marcus, Allison Akana, W. Heinrichs, C. Kirchner, K. O'Hanlan, M. Ruyle, M. Sheehan, H. Judd, G. Greendale, Richard Bayalos, K. Lozano, K. Kawakami, E. Barrett-Connor, R. Langer, D. Kritz-Silverstein, M. Carrion-Petersen, C. Cavero, H. Schrott, Susan Johnson, D. Feddersen, Denise Krutzfeldt, J. Benda, C. Pauerstein, J. Trabal, R. Schenken, M. Stern, Mercedes Rodriguez-Sifuentes, Carann Easton, Wells Hb, M. Espeland, G. Howard, R. Byington, C. Legault, S. Shumaker, P. Hogan, D. Hire, C. Wasilauskas, M. James, Kathy Lane, Tim Terrell, S. Reece, J. Pierce, Megan Snow, S. Anthony, Irma Mebane-Sims, P. Einhorn, S. Hunsberger, M. Waclawiw, K. Lippel, D. Lucas, J. Verter, S. Jackson, J. Kelaghan, J. Perlman, P. Wolf, J. McGowan, Stephen Gordon, S. Heyse, J. Fradkin, S. Sherman, L. Page, Annemette Sorenson, B. Hulka, B. Brody, R. Burkman, R. Heaney, R. Krauss, H. Roberts, J. Wittes, L. Riggs, Richards Moss, J. Albers, S. Marcovina, S. Fineberg, R. Tracy, M. Merino, R. Scully, V. Livolsi, G. Kessler (1995)
Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) TrialJAMA, 273
P. Belchetz (1994)
Hormonal treatment of postmenopausal women.The New England journal of medicine, 330 15
W. Kannel, P. Wolf, W. Castelli, R. D'Agostino (1987)
Fibrinogen and risk of cardiovascular disease. The Framingham Study.JAMA, 258 9
V. Nguyen (1988)
Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987Annals of Emergency Medicine, 17
A. Nabulsi, A. Folsom, Alice White, W. Patsch, G. Heiss, Kenneth Wu, M. Szklo (1993)
Association of Hormone-Replacement Therapy With Various Cardiovascular Risk Factors in Postmenopausal WomenObstetrical & Gynecological Survey, 48
Estrogen is good for a woman's heart. While generally accepted when the estrogen is produced naturally, this theory has been a matter of great controversy when the estrogen is administered "artificially" in hormone replacement therapy (HRT) for women during and after menopause. After a half century of conflicting data, we can affirm with growing confidence that, at the very least, estrogen reduces key cardiovascular risk factors in women at a time when they become especially vulnerable to heart disease, namely, after 50 years of age. See also p 199. In this issue of The Journal, the Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators report on one aspect of the many findings that we can expect to learn over the next few years from their important National Institutes of Health (NIH)-supported multicenter efforts.1 Their report focuses on the effect of HRT, given in four different formulations, compared with short-term use of placebo
JAMA – American Medical Association
Published: Jan 18, 1995
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.